

HCPCS Code	Medication Name	Effective Date
Step Therapy		
Q5126	Alymsys (bevacizumab-maly) injection	10/03/2022
J9035	Avastin (bevacizumab) injection	10/03/2022
J0179	Beovu (brolucizumab-dbll) intravitreal	10/01/2021
Q5124	Byooviz (ranibizumab-nuna) intravitreal	02/06/2023
Q5128	Cimerli (ranibizumab-eqrn) intravitreal	06/01/2024
J2786	Cinqair (reslizumab) injection	01/01/2019
J7318	Durolane (hyaluronate sodium) injection	02/06/2023
J7323	Euflexxa (hyaluronate sodium) injection	06/01/2019
J0178	Eylea (aflibercept) intravitreal	01/01/2019
J0177	Eylea HD (aflibercept HD) intravitreal	06/01/2024
J0517	Fasenra (benralizumab) injection	12/01/2019
Q5108	Fulphila (pegfilgrastim-jmdb) injection	10/03/2022
Q5130	Fylnetra (pegfilgrastim-pbbk)	12/02/2024
J7326	Gel-One (hyaluronate sodium) injection	06/01/2019
J7328	Gelsyn-3 (hyaluronate sodium) injection	02/06/2023
J1745	Generic infliximab intravenous (IV)	02/06/2023
J7320	GenVisc 850 (hyaluronate sodium) injection	06/01/2019
J1447	Granix (tbo-filgrastim) injection	10/03/2022
J9355	Herceptin (trastuzumab) injection	10/03/2022
J9356	Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)	10/03/2022
Q5113	Herzuma (trastuzumab-pkrb) injection	10/03/2022
J7321	Hyalgan (hyaluronate sodium) injection	06/01/2019
J7322	Hymovis (hyaluronate acid) injection	06/01/2019
J1439**	Injectafer (ferric carboxymaltose) intravenous	10/01/2021
J0202	Lemtrada (alemtuzumab) injection	06/01/2019
J2778	Lucentis (ranibizumab) intravitreal	01/01/2019
J1437**	Monoferric (ferric derisomaltose) intravenous	10/01/2021
J7327	Monovisc (hyaluronate acid) injection	06/01/2019
J2506	Neulasta, Neulasta OnPro (pegfilgrastim) injection	10/03/2022

For additional details, please refer to the Prior Authorization Criteria [here](#) and the Step Therapy Criteria [here](#)

*This list is subject to change.

**These products do not require review for patients on dialysis when submitted for reimbursement as part of the End Stage Renal Disease (ESRD) Prospective Payment System (PPS), or "bundled" PPS amount

HCP Code	Medication Name	Effective Date
Step Therapy		
J1442	Neupogen (filgrastim) injection	10/03/2022
J2182	Nucala (mepolizumab) injection	01/01/2019
Q5122	Nyvepria (pegfilgrastim-apgf) injection	10/03/2022
J2350	Ocrevus (ocrelizumab) injection	06/01/2019
Q5112	Ontruzant (trastuzumab-dttb) injection	10/03/2022
Q5125	Releuko (filgrastim-ayow) injection	10/03/2022
J1745	Remicade (infliximab) intravenous (IV)	02/06/2023
Q5104	Renflexis (infliximab-abda) intravenous (IV)	02/06/2023
Q5123	Riabni (rituximab-arrx) injection	10/03/2022
J9312	Rituxan (rituximab) injection	10/03/2022
J9311	Rituxan Hycela (rituximab and hyaluronidase) injection	10/03/2022
J1449	Rolvedon (eflapegrastim-xnst)	09/12/2024
J1300	Soliris (eculizumab) injection	10/03/2022
Q5127	Stimufend (pegfilgrastim-fpgk)	12/02/2024
J7321	Supartz FX (hyaluronate sodium) injection	06/01/2019
J2779	Susvimo (ranibizumab) intravitreal	02/06/2023
J2356	Tezspire (tezepelumab-ekko) injection	02/06/2023
Q5116	Trazimera (trastuzumab-qyyp) injection	10/03/2022
J7332	Triluron (hyaluronate sodium) injection	04/04/2022
J7329	TriVisc (hyaluronate sodium) injection	06/01/2019
J2323	Tysabri (natalizumab) injection	06/01/2019
J2777	Vabysmo (faricimab-svoa) intravitreal	02/06/2023
Q5129	Vegzelma (bevacizumab-adcd)	12/02/2024
J7321	Visco-3 (hyaluronate sodium) injection	06/01/2019
J2357	Xolair (omalizumab) injection	01/01/2019

For additional details, please refer to the Prior Authorization Criteria [here](#) and the Step Therapy Criteria [here](#)

*This list is subject to change.

**These products do not require review for patients on dialysis when submitted for reimbursement as part of the End Stage Renal Disease (ESRD) Prospective Payment System (PPS), or “bundled” PPS amount

HCPCS Code	Medication Name	Effective Date
Prior Authorization		
J1599	Alyglo (immune globulin intravenous, human-stwk)	09/12/2024
J0225	Amvuttra (vutrisiran injection)	09/12/2024
J1554	Asceniv (immune globulin) intravenous (IV)	10/03/2022
Q5121	Avsola (infliximab-axxq) intravenous (IV)	02/06/2023
J1556	Bivigam (immune globulin) intravenous (IV)	10/03/2022
J1551	Cutaquig (immune globulin) subcutaneous (SC)	10/03/2022
J1555	Cuvitru (immune globulin) subcutaneous (SC)	10/03/2022
J3490	Empaveli (pegcetacoplan) subcutaneous infusion	10/03/2022
J3590 C9399	Enspryng (satralizumab-mwge)	10/03/2022
J1572	Flebogamma (immune globulin) intravenous (IV)	10/03/2022
J1569	Gammagard Liquid (immune globulin) intravenous (IV) or subcutaneous (SC)	10/03/2022
J1566	Gammagard S/D (immune globulin) intravenous (IV)	10/03/2022
J1561	Gammaked (immune globulin) intravenous (IV) or subcutaneous (SC)	10/03/2022
J1557	Gammaplex (immune globulin) intravenous (IV)	10/03/2022
J1561	Gamunex-C (immune globulin) intravenous (IV) or subcutaneous (SC)	10/03/2022
J1559	Hizentra (immune globulin) subcutaneous (SC)	10/03/2022
J1575	HyQvia (immune globulin) subcutaneous (SC)	10/03/2022
J1599	Immune Globulin, intravenous, not otherwise specified	10/03/2022
Q5103	Inflectra (infliximab-dyyb) intravenous (IV)	02/06/2023
Q5117	Kanjinti (trastuzumab-anns) injection	10/03/2022
J2507	Krystexxa (pegloticase) injection	10/03/2022
J2820	Leukine (sargramostim) injection	10/03/2022
Q5107	Mvasi (bevacizumab-awwb) injection	10/03/2022
Q5110	Nivestym (filgrastim-aafi) injection	10/03/2022
J1568	Octagam (immune globulin) intravenous (IV)	10/03/2022
Q5114	Ogivri (trastuzumab-dkst) injection	10/03/2022
J0222	Onpattro (patisiran injection)	09/12/2024
J0224	Oxlumo (lumasiran injection)	09/12/2024

For additional details, please refer to the Prior Authorization Criteria [here](#) and the Step Therapy Criteria [here](#)

*This list is subject to change.

**These products do not require review for patients on dialysis when submitted for reimbursement as part of the End Stage Renal Disease (ESRD) Prospective Payment System (PPS), or “bundled” PPS amount

HCPCS Code	Medication Name	Effective Date
Prior Authorization		
J1576	Panzyga (immune globulin) intravenous (IV)	10/03/2022
J1459	Privigen (immune globulin) intravenous (IV)	10/03/2022
J0896	Reblozyl (luspatercept-aamt) injection	10/03/2022
Q5119	Ruxience (rituximab-pvvr) injection	10/03/2022
J9333	Rystiggo (rozanolixizumab injection)	09/12/2024
G2082 G2083	Spravato (esketamine)	09/12/2024
J3241	Tepezza (teprotumumab-trbw) intravenous (IV)	10/03/2022
Q5115	Truxima (rituximab-abbs) injection	10/03/2022
Q5111	Udenyca, Udenyca Onbody (pegfilgrastim-cbqv) injection	10/03/2022
J1303	Ultomiris (ravulizumab-cwvz) intravenous (IV)	10/03/2022
J1823	Uplizna (inebilizumab-cdon) intravenous (IV)	10/03/2022
J9332	Vyvgart (efgartigimod alfa-fcab) intravenous (IV)	10/03/2022
J9334	Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase)	06/01/2024
J1558	Xembify (immune globulin) subcutaneous (SC)	10/03/2022
Q5101	Zarxio (filgrastim-sndz) injection	10/03/2022
Q5120	Ziextenzo (pegfilgrastim-bmez) injection	10/03/2022
Q5118	Zirabev (bevacizumab-bvzr) injection	10/03/2022

For additional details, please refer to the Prior Authorization Criteria [here](#) and the Step Therapy Criteria [here](#)

*This list is subject to change.

**These products do not require review for patients on dialysis when submitted for reimbursement as part of the End Stage Renal Disease (ESRD) Prospective Payment System (PPS), or “bundled” PPS amount